- Full Year Revenues Increased $525 million to $24.6 billion;
Pharmacy Sales Increased 12%
- Full Year Net Loss per Share Increased from $1.87 to $9.96
Driven by Non-Cash Impairment Charges
- Full Year Adjusted EBITDA Increased 16% to $505.9 million
Driven by Strong Retail Pharmacy Performance
- Generated $379 million in Operating Cash Flow and Reduced
Net Debt by $212 million
- Leverage Ratio Improved Year Over Year from 6.7 to 5.4
Times
- Issues Fiscal 2023 Adjusted EBITDA Outlook in Range of $460
million to $500 million – Announces Cost Rationalization Program
that Targets $170 million in Savings
Rite Aid Corporation (NYSE: RAD) today reported operating
results for its fourth quarter and fiscal year ended February 26,
2022.
“We exceeded our 2022 plan amid continuing challenges of the
COVID-19 pandemic. As we look forward to the year ahead, we are
ready and energized to compete in a new post-pandemic normal,” said
Heyward Donigan, president and chief executive officer. “We
demonstrated the important role that pharmacists play in the
everyday health of our customers and are well positioned to grow in
a trillion-dollar pharmacy market through our continued leadership
as a full-service pharmacy company.”
Consolidated Fourth Quarter and Full Year Summary
(dollars in thousands)
Thirteen
Week Period Ended
Fifty-two
Week Period Ended
February
26, 2022
February
27, 2021
February
26, 2022
February
27, 2021
Revenues from continuing operations
$
6,065,390
$
5,916,856
$
24,568,255
$
24,043,240
Net loss from continuing operations
(389,062)
(18,495)
(538,478)
(100,070)
Adjusted EBITDA from continuing
operations
106,075
41,265
505,905
437,665
For the fourth quarter, the company reported net loss from
continuing operations of $389.1 million, or $7.18 loss per share,
Adjusted Net Loss from continuing operations of $88.6 million, or
$1.63 loss per share, and Adjusted EBITDA from continuing
operations of $106.1 million, or 1.8 percent of revenues.
Revenues from continuing operations increased 2.5 percent and
2.2 percent for the thirteen and fifty-two week periods ended
February 26, 2022, respectively, compared to the prior year driven
by growth at the Retail Pharmacy Segment, partially offset by a
decline at the Pharmacy Services Segment.
Fourth quarter net loss from continuing operations was $389.1
million, or $7.18 per share, compared to last year’s fourth quarter
net loss from continuing operations of $18.5 million, or $0.34 per
share. The increase in net loss is due primarily to a current year
charge of $229.0 million for the impairment of goodwill related to
the Pharmacy Services Segment. Other variance drivers include
higher facility exit and impairment charges driven by the Company’s
store closure decisions, a gain on sale of assets in the prior year
fourth quarter resulting from the sale leasebacks of stores and
distribution centers, a gain on the acquisition of Bartell Drugs in
the prior year fourth quarter, and a LIFO charge in the current
quarter compared to a LIFO credit in the prior year fourth quarter.
These items were partially offset by an increase in Adjusted
EBITDA.
Net loss from continuing operations for the fiscal year ended
February 26, 2022, was $538.5 million, or $9.96 loss per share,
compared to last year’s net loss of $100.1 million, or $1.87 loss
per share. The increase in net loss is due primarily to goodwill
impairment related to the Pharmacy Services Segment, higher
facility exit and impairment charges, a LIFO charge in the current
year compared to a LIFO credit in the prior year, higher litigation
settlements, and a gain on the acquisition of Bartell Drugs in the
prior year. These items were partially offset by an increase in
Adjusted EBITDA and lower restructuring-related costs.
Retail Pharmacy Segment
(dollars in thousands)
Thirteen
Week Period Ended
Fifty-two
Week Period Ended
February
26, 2022
February
27, 2021
February
26, 2022
February
27, 2021
Revenues from continuing operations
$
4,433,408
$
4,114,485
$
17,494,816
$
16,365,260
Adjusted EBITDA from continuing
operations
102,419
6,017
392,633
279,896
Retail Pharmacy Segment revenues from continuing operations
increased 7.8 percent over the prior year quarter, driven by an
increase in same store sales. Same store sales from continuing
operations for the fourth quarter increased 8.3 percent over the
prior year period, consisting of a 10.7 percent increase in
pharmacy sales and a 2.7 percent increase in front-end sales.
Front-end same store sales, excluding cigarettes and tobacco
products, increased 3.2 percent. The number of prescriptions filled
in same stores, adjusted to 30-day equivalents, increased 8.7
percent over the prior year period. In addition to the benefit from
3.3 million COVID-19 vaccinations, maintenance prescriptions
increased 1.0 percent while other acute prescriptions increased 9.0
percent on a same store basis when excluding COVID-19 vaccinations.
Prescription sales from continuing operations accounted for 70.1
percent of total drugstore sales. Total store count at the end of
the fourth quarter was 2,450.
For the fiscal year ended February 26, 2022, Retail Pharmacy
Segment revenues from continuing operations increased 6.9 percent
over the prior year, driven by an increase in same store sales and
the inclusion of Bartell’s results. Same store sales from
continuing operations for the year increased 4.5 percent over the
prior year, consisting of a 7.9 percent increase in pharmacy sales,
partially offset by a 3.3 percent decrease in front-end sales.
Front-end same store sales, excluding cigarettes and tobacco
products, decreased 2.8 percent. The number of prescriptions filled
in same stores, adjusted to 30-day equivalents, increased 8.7
percent over the prior year period. In addition to the benefit from
over 14 million COVID-19 vaccinations, maintenance prescriptions
increased 1.8 percent while other acute prescriptions increased 2.3
percent on a same store basis when excluding COVID-19 vaccinations.
Prescription sales from continuing operations accounted for 70.0
percent of total drugstore sales.
Retail Pharmacy Segment Adjusted EBITDA from continuing
operations was $102.4 million, or 2.3 percent of revenues, for the
fourth quarter compared to last year’s fourth quarter Adjusted
EBITDA from continuing operations of $6.0 million, or 0.2 percent
of revenues. The increase in Adjusted EBITDA was due to increased
gross profit, partially offset by an increase in selling, general
and administrative (SG&A) expenses. Gross profit benefited from
higher pharmacy same store sales, including immunizations,
partially offset by pharmacy reimbursement rate pressures and an
increase in front-end gross profit resulting from higher front-end
same store sales and a reduction in markdowns. SG&A expenses
were negatively impacted by incremental payroll costs to support
COVID immunizations, increases in bonus expense for store and
field, increases in workers compensation costs and cycling the
benefit from the prior year change to modernize our associate PTO
plans.
For the fiscal year ended February 26, 2022, Retail Pharmacy
Segment Adjusted EBITDA from continuing operations was $392.6
million, or 2.2 percent of revenues, compared to $279.9 million, or
1.7 percent of revenues, for the prior year. The increase in
Adjusted EBITDA was due to increased gross profit, partially offset
by an increase in selling, general and administrative (SG&A)
expenses. Gross profit benefited from higher pharmacy same store
sales, including immunizations, and incremental gross profit from
our Bartell acquisition. These increases were partially offset by
pharmacy reimbursement rate pressures. SG&A expenses were
negatively impacted by cycling the benefit from the prior year
change to modernize our associate PTO plans, incremental costs from
our Bartell stores, and costs incurred to support our COVID-19
vaccination program, partially offset by labor savings due to the
cycling of the prior year’s Hero Pay and Hero Bonus programs and
the COVID-19 buying surge.
Pharmacy Services Segment
(dollars in thousands)
Thirteen
Week Period Ended
Fifty-two
Week Period Ended
February
26, 2022
February
27, 2021
February
26, 2022
February
27, 2021
Revenues from continuing operations
$
1,693,800
$
1,870,111
$
7,323,125
$
7,970,137
Adjusted EBITDA from continuing
operations
3,656
35,248
113,272
157,769
Pharmacy Services Segment revenues were $1.7 billion for the
quarter, a decrease of 9.4 percent compared to the prior year
quarter. For the fiscal year ended February 26, 2022, Pharmacy
Services Segment revenues were $7.3 billion, a decrease of 8.1
percent compared to the prior year. The decrease in revenues was
primarily the result of a planned decrease in Elixir Insurance
membership and a previously announced client loss due to industry
consolidation.
Pharmacy Services Segment Adjusted EBITDA from continuing
operations was $3.7 million, or 0.2 percent of revenues, for the
fourth quarter compared to last year’s fourth quarter Adjusted
EBITDA from continuing operations of $35.2 million, or 1.9 percent
of revenues. The reduction in Adjusted EBITDA resulted, in part,
from the decline in revenues associated with lost PBM business
discussed above, partially offset by higher retained rebates in the
last two months of the quarter. Also contributing to the reduction
to Adjusted EBITDA in the current quarter was an increase in the
medical loss ratio at Elixir insurance, as the costs for calendar
2021 were in excess of what we had estimated. In addition, we
recorded a reduction in accounts receivable related to a decision
to exit our rebate aggregation business. As reflected in our Fiscal
2023 outlook for Elixir, these items will not be part of Elixir’s
run rate Adjusted EBITDA going forward.
For the fiscal year ended February 26, 2022, Pharmacy Services
Segment Adjusted EBITDA from continuing operations was $113.3
million, or 1.6 percent of revenues, compared to prior year
Adjusted EBITDA from continuing operations of $157.8 million, or
2.0 percent of revenues. Gross profit dollars were negatively
impacted from the decline in revenues, a reduction in rebates, an
increase in the medical loss ratio at Elixir Insurance and the
decision to exit the rebate aggregation business.
Outlook for Fiscal 2023
The Company’s outlook for Fiscal 2023 takes into account an
expected reduction in benefit from COVID vaccinations and a
reduction in revenues at Elixir, offset by anticipated benefit from
initiatives to increase retail sales and non-COVID related
prescriptions. The outlook also assumes improvements in front end
margin driven by changes in our loyalty program, greater owned
brand penetration and expected expansion in gross margin at Elixir
due to our new rebate arrangement, offset by continuing
reimbursement rate pressure. We will significantly reduce costs
through our closure of a total of 145 unprofitable stores (which
includes the 63 announced last quarter), a reduction in corporate
administrative expenses and improved efficiencies in worked payroll
and other store labor costs. We have also reduced expenses at
Elixir associated with our reduction in membership. We expect these
cost initiatives to drive savings of $170 million in Fiscal
2023.
In addition, the following Fiscal 2023 outlook is
forward-looking subject to a range of assumptions and uncertainties
described below and in documents that we file or furnish with the
Securities and Exchange Commission the (“SEC”).
Total revenues are expected to be between $23.1 billion and
$23.5 billion in fiscal 2023. Retail Pharmacy Segment revenue is
expected to be between $17.7 billion and $18.0 billion and Pharmacy
Services Segment revenue is expected to be between $5.4 billion and
$5.5 billion (net of any intercompany revenues to the Retail
Pharmacy Segment).
Net loss is expected to be between $167 million and $210
million.
Adjusted EBITDA is expected to be between $460 million and $500
million. Retail Pharmacy Segment Adjusted EBITDA is expected to be
between $320 million and $350 million and Pharmacy Services Segment
Adjusted EBITDA is expected to be between $140 million and $150
million.
Adjusted net loss per share is expected to be between $(0.53)
and $(1.06).
Capital expenditures are expected to be approximately $250
million, with a focus on investments in digital capabilities,
technology, prescription file purchases, distribution center
automation and store remodels. We expect to generate positive free
cash flow in Fiscal 2023.
Conference Call Broadcast
Rite Aid will hold an analyst call at 8:30 a.m. Eastern Time
today with remarks by Rite Aid's management team. The call will be
broadcast via the Internet at https://investors.riteaid.com. The
telephone replay will be available beginning at 12:00 p.m. Eastern
Time on April 14, 2022, and ending at 11:59 p.m. Eastern Time on
May 14, 2022. To access the replay of the call, telephone (800)
770-2030 or (647) 362-9199 and enter the seven-digit reservation
number 9029129. The webcast replay of the call will also be
available at https://investors.riteaid.com starting at 12 p.m.
Eastern Time today. The playback will be available until the
company’s next conference call.
About Rite Aid Corporation
Rite Aid Corporation is on the front lines of delivering
healthcare services and retail products to Americans 365 days a
year. Our pharmacists are uniquely positioned to engage with
customers and improve their health outcomes. We provide an array of
whole being health products and services for the entire family
through over 2,400 retail pharmacy locations across 17 states.
Through Elixir, we provide pharmacy benefits and services to
millions of members nationwide. For more information, visit
www.riteaid.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this release that are not historical, are
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such statements include, but are not limited to, statements
regarding Rite Aid's outlook and guidance for fiscal 2023; the
continued impact of the global coronavirus (COVID-19) pandemic on
Rite Aid’s business; Rite Aid’s store closure program; and any
assumptions underlying any of the foregoing. Words such as
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "predict," "project," "should," and "will"
and variations of such words and similar expressions are intended
to identify such forward-looking statements.
These forward-looking statements are not guarantees of future
performance and involve risks, assumptions and uncertainties,
including, but not limited to: risks related to the prolonged
impact of the COVID-19 global pandemic and the emerging new
variants, including the government responses thereto; the impact of
COVID-19 on our workforce, operations, stores, expenses, and supply
chain, and the operations or behaviors of our customers, suppliers
and business partners; our ability to successfully implement our
store closure program and other strategies; the impact of our high
level of indebtedness, the ability to refinance such indebtedness
on acceptable terms and our ability to satisfy our obligations and
the other covenants contained in our debt agreements; outcome of
pending or new litigation, including related to Opioids, “usual and
customary” pricing or other matters; our ability to monetize the
CMS receivable created in our Part D business; general competitive,
economic, industry, market, political (including healthcare reform)
and regulatory conditions (including changes to laws or regulations
relating to labor or wages), as well as other factors that impact
the markets in which we operate; the impact of private and public
third-party payers continued reduction in prescription drug
reimbursements and efforts to encourage mail order; our ability to
manage expenses and our investments in working capital; our ability
to achieve the benefits of our efforts to reduce the costs of our
generic and other drugs; our ability to achieve cost savings and
other benefits of our restructuring efforts within our anticipated
timeframe, if at all; the outcome of our continuing efforts to
monitor and comply with applicable laws, regulations, policies and
procedures; and our ability to partner and have relationships with
health plans and health systems.
These and other risks, assumptions and uncertainties are more
fully described in Item 1A (Risk Factors) of our most recent Annual
Report on Form 10-K and in other documents that we file or furnish
with the Securities and Exchange Commission (the “SEC”), which you
are encouraged to read. To the extent that COVID-19 adversely
affects our business and financial results, it may also have the
effect of heightening many of such risk factors.
Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results
may vary materially from those indicated or anticipated by such
forward-looking statements. Accordingly, you are cautioned not to
rely on these forward-looking statements, which speak only as of
the date they are made.
The degree to which COVID-19 may adversely affect Rite Aid’s
results and operations, including its ability to achieve its
outlook for fiscal 2023 guidance, will depend on numerous evolving
factors and future developments, which are highly uncertain,
including, but not limited to, federal, state and local
governmental policies and initiatives designed to reduce the
transmission of COVID-19 and emerging new variants and how quickly
and to what extent normal economic and operating conditions can
resume. As a result, the impact on Rite Aid’s financial and
operating results cannot be reasonably estimated with specificity
at this time, but the impact could be material. Rite Aid expressly
disclaims any current intention, and assumes no duty, to update
publicly any forward-looking statement after the distribution of
this release, whether as a result of new information, future
events, changes in assumptions or otherwise.
All references to “Company” and “Rite Aid” as used throughout
this release refer to Rite Aid Corporation and its affiliates.
Reconciliation of Non-GAAP Financial Measures
Rite Aid separately reports financial results on the basis of
Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted
Share, Adjusted EBITDA, Adjusted EBITDA Gross Profit and Adjusted
EBITDA SG&A, which are non-GAAP financial measures. See the
attached tables for a reconciliation of Adjusted Net Income (Loss),
Adjusted Net Income (Loss) per Diluted Share and Adjusted EBITDA to
net income (loss), and net income (loss) per diluted share, which
are the most directly comparable GAAP financial measures. Adjusted
Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share
exclude amortization expense, merger and acquisition-related costs,
non-recurring litigation settlements, gains or losses on debt
modifications and retirements, LIFO adjustments, goodwill and
intangible asset impairment charges, restructuring-related costs,
the gain or loss on Bartell acquisition, and the change in estimate
related to manufacturer rebate receivables. Rite Aid believes
Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per
Diluted Share serve as appropriate measures to be used in
evaluating the performance of its business and help its investors
better compare its operating performance over multiple periods.
Adjusted EBITDA is defined as net income (loss) excluding the
impact of income taxes, interest expense, depreciation and
amortization, LIFO adjustments, charges or credits for facility
exit and impairment, goodwill and intangible asset impairment
charges, inventory write-downs related to store closings, gains or
losses on debt modifications and retirements, and other items
(including stock-based compensation expense, merger and
acquisition-related costs, non-recurring litigation settlements,
severance, restructuring-related costs, costs related to facility
closures, gain or loss on sale of assets, the gain or loss on
Bartell acquisition, and the change in estimate related to
manufacturer rebate receivables). The add back of LIFO (credit)
charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss)
and Adjusted Net Income (Loss) per Diluted Share removes the entire
impact of LIFO (credits) charges, and effectively reflects Rite
Aid's results as if the company was on a FIFO inventory basis. Rite
Aid believes Adjusted EBITDA serves as an appropriate measure in
evaluating the performance of its business and helps its investors
better compare its operating performance with its competitors.
Adjusted EBITDA Gross Profit includes LIFO adjustments,
depreciation and amortization (COGS portion only) and other items.
See the attached tables for a reconciliation of Adjusted EBITDA
Gross Profit to Revenue, which is the most directly comparable GAAP
financial measure. Adjusted EBITDA SG&A excludes depreciation
and amortization (SG&A portion only), stock-based compensation
expense, merger and acquisition-related costs, litigation
settlements and other items. See the attached tables for a
reconciliation of Adjusted EBITDA SG&A to Revenue, which is the
most directly comparable GAAP financial measure. The Company
believes Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A
serve as appropriate measures in evaluating the performance of its
business and helps its investors better compare its operating
performance with its competitors.
RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE
SHEETS (Dollars in thousands) (unaudited) February 26, 2022
February 27, 2021 ASSETS Current assets: Cash and cash equivalents
$
39,721
$
160,902
Accounts receivable, net
1,343,496
1,462,441
Inventories, net of LIFO reserve of $487,173 and $485,859
1,959,389
1,864,890
Prepaid expenses and other current assets
106,749
106,941
Total current assets
3,449,355
3,595,174
Property, plant and equipment, net
989,167
1,080,499
Operating lease right-of-use assets
2,813,535
3,064,077
Goodwill
879,136
1,108,136
Other intangibles, net
291,196
340,519
Deferred tax assets
20,071
14,964
Other assets
86,543
132,035
Total assets
$
8,529,003
$
9,335,404
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:
Current maturities of long-term debt and lease financing
obligations
$
5,544
$
6,409
Accounts payable
1,571,261
1,437,421
Accrued salaries, wages and other current liabilities
780,632
642,364
Current portion of operating lease liabilities
575,651
516,752
Total current liabilities
2,933,088
2,602,946
Long-term debt, less current maturities
2,732,986
3,063,087
Long-term operating lease liabilities
2,597,090
2,829,293
Lease financing obligations, less current maturities
14,830
16,711
Other noncurrent liabilities
151,976
208,213
Total liabilities
8,429,970
8,720,250
Commitments and contingencies
-
-
Stockholders' equity: Common stock
55,752
55,143
Additional paid-in capital
5,910,299
5,897,168
Accumulated deficit
(5,851,581
)
(5,313,103
)
Accumulated other comprehensive loss
(15,437
)
(24,054
)
Total stockholders' equity
99,033
615,154
Total liabilities and stockholders' equity
$
8,529,003
$
9,335,404
RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED
STATEMENTS OF OPERATIONS (Dollars in thousands, except per share
amounts) (unaudited)
Thirteen weeks ended
February 26, 2022
Thirteen weeks ended
February 27, 2021
Revenues
$
6,065,390
$
5,916,856
Costs and expenses: Cost of revenues
4,824,077
4,774,297
Selling, general and administrative expenses
1,243,841
1,187,541
Facility exit and impairment charges
112,551
35,669
Goodwill and intangible asset impairment charges
229,000
-
Interest expense
46,094
49,999
Loss (gain) on sale of assets, net
5,584
(51,827
)
Gain on Bartell acquisition
-
(47,705
)
6,461,147
5,947,974
Loss from continuing operations before income taxes
(395,757
)
(31,118
)
Income tax benefit
(6,695
)
(12,623
)
Net loss from continuing operations
(389,062
)
(18,495
)
Net income from discontinued operations, net of tax
-
-
Net loss
$
(389,062
)
$
(18,495
)
Basic and diluted loss per share: Numerator for loss
per share: Net loss from continuing operations attributable to
common stockholders - basic and diluted
$
(389,062
)
$
(18,495
)
Net income from discontinued operations attributable to common
stockholders - basic and diluted
-
-
Loss attributable to common stockholders - basic and diluted
$
(389,062
)
$
(18,495
)
Denominator: Basic and diluted weighted average shares
54,208
53,812
Basic and diluted loss per share Continuing operations
$
(7.18
)
$
(0.34
)
Discontinued operations
$
-
$
-
Net basic and diluted loss per share
$
(7.18
)
$
(0.34
)
RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED
STATEMENTS OF OPERATIONS (Dollars in thousands, except per share
amounts) (unaudited)
Fifty-two weeks ended
February 26, 2022
Fifty-two weeks ended
February 27, 2021
Revenues
$
24,568,255
$
24,043,240
Costs and expenses: Cost of revenues
19,461,760
19,338,918
Selling, general and administrative expenses
5,033,876
4,657,185
Facility exit and impairment charges
180,190
58,403
Goodwill and intangible asset impairment charges
229,000
29,852
Interest expense
191,601
201,388
Loss (gain) on debt modifications and retirements, net
3,235
(5,274
)
Loss (gain) on sale of assets, net
5,505
(69,300
)
Loss (gain) on Bartell acquisition
5,346
(47,705
)
25,110,513
24,163,467
Loss from continuing operations before income taxes
(542,258
)
(120,227
)
Income tax benefit
(3,780
)
(20,157
)
Net loss from continuing operations
(538,478
)
(100,070
)
Net income from discontinued operations, net of tax
-
9,161
Net loss
$
(538,478
)
$
(90,909
)
Basic and diluted loss per share: Numerator for loss
per share: Net loss from continuing operations attributable to
common stockholders - basic and diluted
$
(538,478
)
$
(100,070
)
Net income from discontinued operations attributable to common
stockholders - basic and diluted
-
9,161
Loss attributable to common stockholders - basic and diluted
$
(538,478
)
$
(90,909
)
Denominator: Basic and diluted weighted average shares
54,055
53,653
Basic and diluted loss per share Continuing operations
$
(9.96
)
$
(1.87
)
Discontinued operations
$
-
$
0.18
Net basic and diluted loss per share
$
(9.96
)
$
(1.69
)
RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED
STATEMENTS OF CASH FLOWS (Dollars in thousands) (unaudited)
Thirteen weeks ended
February 26, 2022
Thirteen weeks ended
February 27, 2021
OPERATING ACTIVITIES: Net loss
$
(389,062
)
$
(18,495
)
Net income from discontinued operations, net of tax
-
-
Net loss from continuing operations
$
(389,062
)
$
(18,495
)
Adjustments to reconcile to net cash provided by operating
activities of continuing operations: Depreciation and amortization
72,995
77,568
Facility exit and impairment charges
112,551
35,669
Goodwill and intangible asset impairment charges
229,000
-
LIFO charge (credit)
414
(21,389
)
Loss (gain) on sale of assets, net
5,584
(51,827
)
Change in allowances for uncollectible accounts receivable
1,019
-
Gain on Bartell acquisition
-
(47,705
)
Stock-based compensation expense
4,230
4,326
Changes in deferred taxes
(5,107
)
(10,633
)
Changes in operating assets and liabilities: Accounts receivable
473,157
325,374
Inventories
(9,962
)
196,795
Accounts payable
9,792
(36,832
)
Operating lease right-of-use assets and operating lease liabilities
(9,858
)
(2,725
)
Other assets
(1,209
)
5,710
Other liabilities
(150,832
)
(96,814
)
Net cash provided by operating activities of continuing operations
342,712
359,022
INVESTING ACTIVITIES: Payments for property, plant and equipment
(49,089
)
(67,752
)
Intangible assets acquired
(2,334
)
(1,097
)
Acquisition of business, net of cash acquired
-
(86,230
)
Proceeds from dispositions of assets and investments
10,885
2,358
Proceeds from sale-leaseback transactions
17,708
88,880
Net cash used in investing activities of continuing operations
(22,830
)
(63,841
)
FINANCING ACTIVITIES: Net payments to revolver
(441,000
)
(141,000
)
Principal payments on long-term debt
(1,016
)
(1,161
)
Change in zero balance cash accounts
6,802
(42,008
)
Net proceeds from the issuance of common stock
-
53
Payments for taxes related to net share settlement of equity awards
(236
)
(921
)
Deferred financing costs paid
-
(55
)
Net cash used in financing activities of continuing operations
(435,450
)
(185,092
)
(Decrease) increase in cash and cash equivalents
(115,568
)
110,089
Cash and cash equivalents, beginning of period
155,289
50,813
Cash and cash equivalents, end of period
$
39,721
$
160,902
RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED
STATEMENTS OF CASH FLOWS (Dollars in thousands) (unaudited)
Fifty-two weeks ended February
26, 2022
Fifty-two weeks ended February
27, 2021
OPERATING ACTIVITIES: Net loss
$
(538,478
)
$
(90,909
)
Net income from discontinued operations, net of tax
-
9,161
Net loss from continuing operations
$
(538,478
)
$
(100,070
)
Adjustments to reconcile to net cash provided by operating
activities of continuing operations: Depreciation and amortization
295,686
327,124
Facility exit and impairment charges
180,190
58,403
Goodwill and intangible asset impairment charges
229,000
29,852
LIFO charge (credit)
1,314
(51,692
)
Loss (gain) on sale of assets, net
5,505
(69,300
)
Change in allowances for uncollectible accounts receivable
22,011
-
Loss (gain) on Bartell acquisition
5,346
(47,705
)
Stock-based compensation expense
13,050
13,003
Loss (gain) on debt modifications and retirements, net
3,235
(5,274
)
Changes in deferred taxes
(6,709
)
(10,633
)
Changes in operating assets and liabilities: Accounts receivable
54,086
(182,404
)
Inventories
(97,112
)
177,263
Accounts payable
139,228
(35,372
)
Operating lease right-of-use assets and operating lease liabilities
(29,375
)
(28,044
)
Other assets
33,737
80,975
Other liabilities
68,558
(50,947
)
Net cash provided by operating activities of continuing operations
379,272
105,179
INVESTING ACTIVITIES: Payments for property, plant and equipment
(194,090
)
(195,141
)
Intangible assets acquired
(26,623
)
(29,800
)
Acquisition of business, net of cash acquired
-
(86,230
)
Proceeds from insured loss
10,436
12,500
Proceeds from dispositions of assets and investments
18,706
11,444
Proceeds from sale-leaseback transactions
57,498
177,892
Net cash used in investing activities of continuing operations
(134,073
)
(109,335
)
FINANCING ACTIVITIES: Proceeds from issuance of long-term debt
350,000
849,918
Net (payments to) proceeds from revolver
(141,000
)
200,000
Principal payments on long-term debt
(545,036
)
(1,058,537
)
Change in zero balance cash accounts
(8,285
)
(36,463
)
Net proceeds from the issuance of common stock
-
53
Financing fees paid for early debt redemption
(833
)
(2,399
)
Payments for taxes related to net share settlement of equity awards
(2,588
)
(3,086
)
Deferred financing costs paid
(18,638
)
(14,729
)
Net cash used in financing activities of continuing operations
(366,380
)
(65,243
)
Cash flows from discontinued operations: Operating activities of
discontinued operations
-
(82,189
)
Investing activities of discontinued operations
-
94,310
Net cash provided by discontinued operations
-
12,121
Decrease in cash and cash equivalents
(121,181
)
(57,278
)
Cash and cash equivalents, beginning of period
160,902
218,180
Cash and cash equivalents, end of period
$
39,721
$
160,902
RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL SEGMENT
OPERATING INFORMATION (Dollars in thousands) (unaudited)
Thirteen weeks ended
February 26, 2022
Thirteen weeks ended
February 27, 2021
Retail Pharmacy Segment Revenues from continuing
operations (a)
$
4,433,408
$
4,114,485
Cost of revenues from continuing operations (a)
3,254,866
3,081,851
Gross profit from continuing operations
1,178,542
1,032,634
LIFO charge (credit) from continuing operations
414
(21,389
)
FIFO gross profit from continuing operations
1,178,956
1,011,245
Adjusted EBITDA gross profit from continuing operations
1,185,144
1,009,004
Gross profit as a percentage of revenues - continuing
operations
26.58
%
25.10
%
LIFO charge (credit) as a percentage of revenues - continuing
operations
0.01
%
-0.52
%
FIFO gross profit as a percentage of revenues - continuing
operations
26.59
%
24.58
%
Adjusted EBITDA gross profit as a percentage of revenues -
continuing operations
26.73
%
24.52
%
Selling, general and administrative expenses from continuing
operations
1,151,411
1,093,074
Adjusted EBITDA selling, general and administrative expenses from
continuing operations
1,082,725
1,002,987
Selling, general and administrative expenses as a percentage of
revenues - continuing operations
25.97
%
26.57
%
Adjusted EBITDA selling, general and administrative expenses as a
percentage of revenues - continuing operations
24.42
%
24.38
%
Cash interest expense
43,721
46,671
Non-cash interest expense
2,373
3,328
Total interest expense
46,094
49,999
Interest expense - continuing operations
46,094
49,999
Interest expense - discontinued operations
-
-
Adjusted EBITDA - continuing operations
102,419
6,017
Adjusted EBITDA as a percentage of revenues - continuing operations
2.31
%
0.15
%
Pharmacy Services Segment Revenues (a)
$
1,693,800
$
1,870,111
Cost of revenues (a)
1,631,029
1,760,186
Gross profit
62,771
109,925
Gross profit as a percentage of revenues
3.71
%
5.88
%
Adjusted EBITDA
3,656
35,248
Adjusted EBITDA as a percentage of revenues
0.22
%
1.88
%
(a) - Revenues and cost of revenues include $61,818 and $67,740 of
inter-segment activity for the thirteen weeks ended February 26,
2022 and February 27, 2021, respectively, that is eliminated in
consolidation. RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL SEGMENT OPERATING INFORMATION (Dollars in thousands)
(unaudited) Fifty-two weeks endedFebruary 26, 2022 Fifty-two
weeks endedFebruary 27, 2021
Retail Pharmacy Segment
Revenues from continuing operations (a)
$
17,494,816
$
16,365,260
Cost of revenues from continuing operations (a)
12,772,741
12,109,469
Gross profit from continuing operations
4,722,075
4,255,791
LIFO charge (credit) from continuing operations
1,314
(51,692
)
FIFO gross profit from continuing operations
4,723,389
4,204,099
Adjusted EBITDA gross profit from continuing operations
4,737,032
4,236,200
Gross profit as a percentage of revenues - continuing
operations
26.99
%
26.01
%
LIFO charge (credit) as a percentage of revenues - continuing
operations
0.01
%
-0.32
%
FIFO gross profit as a percentage of revenues - continuing
operations
27.00
%
25.69
%
Adjusted EBITDA gross profit as a percentage of revenues -
continuing operations
27.08
%
25.89
%
Selling, general and administrative expenses from continuing
operations
4,656,776
4,299,152
Adjusted EBITDA selling, general and administrative expenses from
continuing operations
4,344,399
3,956,304
Selling, general and administrative expenses as a percentage of
revenues - continuing operations
26.62
%
26.27
%
Adjusted EBITDA selling, general and administrative expenses as a
percentage of revenues - continuing operations
24.83
%
24.18
%
Cash interest expense
180,197
188,306
Non-cash interest expense
11,404
13,082
Total interest expense
191,601
201,388
Interest expense - continuing operations
191,601
201,388
Interest expense - discontinued operations
-
-
Adjusted EBITDA - continuing operations
392,633
279,896
Adjusted EBITDA as a percentage of revenues - continuing operations
2.24
%
1.71
%
Pharmacy Services Segment Revenues (a)
$
7,323,125
$
7,970,137
Cost of revenues (a)
6,938,705
7,521,606
Gross profit
384,420
448,531
Gross profit as a percentage of revenues
5.25
%
5.63
%
Adjusted EBITDA
113,272
157,769
Adjusted EBITDA as a percentage of revenues
1.55
%
1.98
%
(a) - Revenues and cost of revenues include $249,686 and $292,157
of inter-segment activity for the fifty-two weeks ended February
26, 2022 and February 27, 2021, respectively, that is eliminated in
consolidation. RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL
INFORMATION RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (In
thousands) (unaudited)
Thirteen weeks ended
February 26, 2022
Thirteen weeks ended
February 27, 2021
Reconciliation of net loss to adjusted EBITDA: Net
loss - continuing operations
$
(389,062
)
$
(18,495
)
Adjustments: Interest expense
46,094
49,999
Income tax benefit
(6,695
)
(12,623
)
Depreciation and amortization
72,995
77,568
LIFO charge (credit)
414
(21,389
)
Facility exit and impairment charges
112,551
35,669
Goodwill and intangible asset impairment charges
229,000
-
Merger and Acquisition-related costs
678
9,413
Stock-based compensation expense
4,230
4,326
Restructuring-related costs
9,948
13,456
Inventory write-downs related to store closings
3,942
1,113
Loss (gain) on sale of assets, net
5,584
(51,827
)
Gain on Bartell acquisition
-
(47,705
)
Change in estimate related to manufacturer rebate receivables
15,068
-
Other
1,328
1,760
Adjusted EBITDA - continuing operations
$
106,075
$
41,265
Percent of revenues - continuing operations
1.75
%
0.70
%
RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (In thousands)
(unaudited) Fifty-two weeks endedFebruary 26, 2022 Fifty-two
weeks endedFebruary 27, 2021 Reconciliation of net
loss to adjusted EBITDA: Net loss - continuing operations
$
(538,478
)
$
(100,070
)
Adjustments: Interest expense
191,601
201,388
Income tax benefit
(3,780
)
(20,157
)
Depreciation and amortization
295,686
327,124
LIFO charge (credit)
1,314
(51,692
)
Facility exit and impairment charges
180,190
58,403
Goodwill and intangible asset impairment charges
229,000
29,852
Loss (gain) on debt modifications and retirements, net
3,235
(5,274
)
Merger and Acquisition-related costs
12,797
10,549
Stock-based compensation expense
13,050
13,003
Restructuring-related costs
35,121
84,552
Inventory write-downs related to store closings
5,298
3,709
Litigation settlements
50,212
-
Loss (gain) on sale of assets, net
5,505
(69,300
)
Loss (gain) on Bartell acquisition
5,346
(47,705
)
Change in estimate related to manufacturer rebate receivables
15,068
-
Other
4,740
3,283
Adjusted EBITDA - continuing operations
$
505,905
$
437,665
Percent of revenues - continuing operations
2.06
%
1.82
%
RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION
ADJUSTED NET LOSS (Dollars in thousands, except per share amounts)
(unaudited)
Thirteen weeks ended
February 26, 2022
Thirteen weeks ended
February 27, 2021
Net loss from continuing operations
$
(389,062
)
$
(18,495
)
Add back - Income tax benefit
(6,695
)
(12,623
)
Loss before income taxes - continuing operations
(395,757
)
(31,118
)
Adjustments: Amortization expense
18,854
20,669
LIFO charge (credit)
414
(21,389
)
Goodwill and intangible asset impairment charges
229,000
-
Merger and Acquisition-related costs
678
9,413
Restructuring-related costs
9,948
13,456
Gain on Bartell acquisition
-
(47,705
)
Change in estimate related to manufacturer rebate receivables
15,068
-
Adjusted loss before income taxes - continuing operations
(121,795
)
(56,674
)
Adjusted income tax benefit (a)
(33,238
)
(14,905
)
Adjusted net loss from continuing operations
$
(88,557
)
$
(41,769
)
Adjusted net loss per diluted share - continuing operations:
Numerator for adjusted net loss per diluted share: Adjusted
net loss from continuing operations
$
(88,557
)
$
(41,769
)
Denominator: Basic and diluted weighted average shares
54,208
53,812
Net loss from continuing operations per diluted share -
continuing operations
$
(7.18
)
$
(0.34
)
Adjusted net loss per diluted share - continuing operations
$
(1.63
)
$
(0.78
)
(a)
The fiscal year 2022 and 2021
annual effective tax rates, calculated using a federal rate plus a
net state rate that excluded the impact of state NOL's, state
credits and valuation allowance, was used for the thirteen weeks
ended February 26, 2022 and February 27, 2021, respectively.
RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION
ADJUSTED NET LOSS (Dollars in thousands, except per share amounts)
(unaudited) Fifty-two weeks endedFebruary 26, 2022 Fifty-two
weeks endedFebruary 27, 2021 Net loss from continuing
operations
$
(538,478
)
$
(100,070
)
Add back - Income tax benefit
(3,780
)
(20,157
)
Loss before income taxes - continuing operations
(542,258
)
(120,227
)
Adjustments: Amortization expense
78,047
89,020
LIFO charge (credit)
1,314
(51,692
)
Goodwill and intangible asset impairment charges
229,000
29,852
Loss (gain) on debt modifications and retirements, net
3,235
(5,274
)
Merger and Acquisition-related costs
12,797
10,549
Restructuring-related costs
35,121
84,552
Loss (gain) on Bartell acquisition
5,346
(47,705
)
Change in estimate related to manufacturer rebate receivables
15,068
-
Litigation settlements
50,212
-
Adjusted loss before income taxes - continuing operations
(112,118
)
(10,925
)
Adjusted income tax benefit (a)
(30,597
)
(2,873
)
Adjusted net loss from continuing operations
$
(81,521
)
$
(8,052
)
Adjusted net loss per diluted share - continuing operations:
Numerator for adjusted net loss per diluted share: Adjusted
net loss from continuing operations
$
(81,521
)
$
(8,052
)
Denominator: Basic and diluted weighted average shares
54,055
53,653
Net loss from continuing operations per diluted share -
continuing operations
$
(9.96
)
$
(1.87
)
Adjusted net loss per diluted share - continuing operations
$
(1.51
)
$
(0.15
)
(a)
The fiscal year 2022 and 2021 annual effective tax rates,
calculated using a federal rate plus a net state rate that excluded
the impact of state NOL's, state credits and valuation allowance,
was used for the fifty-two weeks ended February 26, 2022 and
February 27, 2021, respectively. RITE AID CORPORATION AND
SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF ADJUSTED
EBITDA GROSS PROFIT AND RECONCILIATION OF ADJUSTED EBITDA SELLING,
GENERAL AND ADMINISTRATIVE EXPENSES- RETAIL PHARMACY SEGMENT (In
thousands) (unaudited)
Thirteen weeks ended
February 26, 2022
Thirteen weeks ended
February 27, 2021
Reconciliation of adjusted EBITDA gross profit:
Revenues
$
4,433,408
$
4,114,485
Gross Profit
1,178,542
1,032,634
Addback: LIFO charge (credit)
414
(21,389
)
Depreciation and amortization (cost of goods sold portion only)
3,339
1,915
Restructuring-related costs - SKU optimization charges
-
(4,824
)
Other
2,849
668
Adjusted EBITDA gross profit - continuing operations
$
1,185,144
$
1,009,004
Percent of revenues - continuing operations
26.73
%
24.52
%
Reconciliation of adjusted EBITDA selling, general and
administrative expenses: Revenues
$
4,433,408
$
4,114,485
Selling, general and administrative expenses
1,151,411
1,093,074
Less: Depreciation and amortization (SG&A portion only)
57,311
61,861
Stock-based compensation expense
3,990
3,809
Merger and Acquisition-related costs
678
9,413
Restructuring-related costs
4,286
12,641
Other
2,421
2,363
Adjusted EBITDA selling, general and administrative expenses -
continuing operations
$
1,082,725
$
1,002,987
Percent of revenues - continuing operations
24.42
%
24.38
%
Adjusted EBITDA - continuing operations
$
102,419
$
6,017
RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION
RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT AND RECONCILIATION
OF ADJUSTED EBITDA SELLING, GENERAL AND ADMINISTRATIVE EXPENSES-
RETAIL PHARMACY SEGMENT (In thousands) (unaudited) Fifty-two
weeks endedFebruary 26, 2022 Fifty-two weeks endedFebruary 27, 2021
Reconciliation of adjusted EBITDA gross profit:
Revenues
$
17,494,816
$
16,365,260
Gross Profit
4,722,075
4,255,791
Addback: LIFO charge (credit)
1,314
(51,692
)
Depreciation and amortization (cost of goods sold portion only)
9,875
8,690
Restructuring-related costs - SKU optimization charges
-
20,939
Other
3,768
2,472
Adjusted EBITDA gross profit - continuing operations
$
4,737,032
$
4,236,200
Percent of revenues - continuing operations
27.08
%
25.89
%
Reconciliation of adjusted EBITDA selling, general and
administrative expenses: Revenues
$
17,494,816
$
16,365,260
Selling, general and administrative expenses
4,656,776
4,299,152
Less: Depreciation and amortization (SG&A portion only)
234,247
261,295
Stock-based compensation expense
12,282
11,594
Merger and Acquisition-related costs
12,797
10,549
Restructuring-related costs
12,237
54,633
Litigation settlements
34,448
-
Other
6,366
4,777
Adjusted EBITDA selling, general and administrative expenses -
continuing operations
$
4,344,399
$
3,956,304
Percent of revenues - continuing operations
24.83
%
24.18
%
Adjusted EBITDA - continuing operations
$
392,633
$
279,896
RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE
YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited)
Guidance Range Low High Total Revenues
$
23,100,000
$
23,500,000
Pharmacy Services Segment Revenues
$
5,450,000
$
5,550,000
Gross Capital Expenditures
$
250,000
$
250,000
Reconciliation of net loss to adjusted EBITDA: Net loss
$
(210,000
)
$
(167,000
)
Adjustments: Interest expense
200,000
200,000
Income tax benefit
(15,000
)
(18,000
)
Depreciation and amortization
300,000
300,000
LIFO charge
15,000
15,000
Facility exit and impairment charges
98,000
98,000
Restructuring-related costs
59,000
59,000
Gain on sale of assets, net
(15,000
)
(15,000
)
Other
28,000
28,000
Adjusted EBITDA
$
460,000
$
500,000
RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET LOSS GUIDANCE
YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited)
Guidance Range Low High Net loss
$
(210,000
)
$
(167,000
)
Add back - income tax benefit
(15,000
)
(18,000
)
Loss before income taxes
(225,000
)
(185,000
)
Adjustments: Amortization expense
71,000
71,000
LIFO charge
15,000
15,000
Restructuring-related costs
59,000
59,000
Adjusted loss before adjusted income taxes
(80,000
)
(40,000
)
Adjusted income tax benefit
(22,000
)
(11,000
)
Adjusted net loss
$
(58,000
)
$
(29,000
)
Diluted adjusted net loss per share
$
(1.06
)
$
(0.53
)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220413005839/en/
INVESTORS: Byron Purcell (717) 975-3710 investor@riteaid.com
MEDIA: Terri Hickey (717) 975-5718 press@riteaid.com
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Sep 2023 to Sep 2024